Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Molecular mechanism of HNF-1A-mediated HNF4A gene regulation and promoter-driven HNF4A-MODY diabetes

L. Kind, J. Molnes, E. Tjora, A. Raasakka, M. Myllykoski, K. Colclough, C. Saint-Martin, C. Adelfalk, P. Dusatkova, S. Pruhova, C. Valtonen-André, C. Bellanné-Chantelot, T. Arnesen, P. Kursula, PR. Njølstad

. 2024 ; 9 (11) : . [pub] 20240610

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013537

Monogenic diabetes is a gateway to precision medicine through molecular mechanistic insight. Hepatocyte nuclear factor 1A (HNF-1A) and HNF-4A are transcription factors that engage in crossregulatory gene transcription networks to maintain glucose-stimulated insulin secretion in pancreatic β cells. Variants in the HNF1A and HNF4A genes are associated with maturity-onset diabetes of the young (MODY). Here, we explored 4 variants in the P2-HNF4A promoter region: 3 in the HNF-1A binding site and 1 close to the site, which were identified in 63 individuals from 21 families of different MODY disease registries across Europe. Our goal was to study the disease causality for these variants and to investigate diabetes mechanisms on the molecular level. We solved a crystal structure of HNF-1A bound to the P2-HNF4A promoter and established a set of techniques to probe HNF-1A binding and transcriptional activity toward different promoter variants. We used isothermal titration calorimetry, biolayer interferometry, x-ray crystallography, and transactivation assays, which revealed changes in HNF-1A binding or transcriptional activities for all 4 P2-HNF4A variants. Our results suggest distinct disease mechanisms of the promoter variants, which can be correlated with clinical phenotype, such as age of diagnosis of diabetes, and be important tools for clinical utility in precision medicine.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013537
003      
CZ-PrNML
005      
20240905134328.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1172/jci.insight.175278 $2 doi
035    __
$a (PubMed)38855865
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kind, Laura $u Department of Biomedicine and $u Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway
245    10
$a Molecular mechanism of HNF-1A-mediated HNF4A gene regulation and promoter-driven HNF4A-MODY diabetes / $c L. Kind, J. Molnes, E. Tjora, A. Raasakka, M. Myllykoski, K. Colclough, C. Saint-Martin, C. Adelfalk, P. Dusatkova, S. Pruhova, C. Valtonen-André, C. Bellanné-Chantelot, T. Arnesen, P. Kursula, PR. Njølstad
520    9_
$a Monogenic diabetes is a gateway to precision medicine through molecular mechanistic insight. Hepatocyte nuclear factor 1A (HNF-1A) and HNF-4A are transcription factors that engage in crossregulatory gene transcription networks to maintain glucose-stimulated insulin secretion in pancreatic β cells. Variants in the HNF1A and HNF4A genes are associated with maturity-onset diabetes of the young (MODY). Here, we explored 4 variants in the P2-HNF4A promoter region: 3 in the HNF-1A binding site and 1 close to the site, which were identified in 63 individuals from 21 families of different MODY disease registries across Europe. Our goal was to study the disease causality for these variants and to investigate diabetes mechanisms on the molecular level. We solved a crystal structure of HNF-1A bound to the P2-HNF4A promoter and established a set of techniques to probe HNF-1A binding and transcriptional activity toward different promoter variants. We used isothermal titration calorimetry, biolayer interferometry, x-ray crystallography, and transactivation assays, which revealed changes in HNF-1A binding or transcriptional activities for all 4 P2-HNF4A variants. Our results suggest distinct disease mechanisms of the promoter variants, which can be correlated with clinical phenotype, such as age of diagnosis of diabetes, and be important tools for clinical utility in precision medicine.
650    12
$a hepatocytární jaderný faktor 4 $x genetika $x metabolismus $7 D051557
650    _2
$a lidé $7 D006801
650    12
$a hepatocytární jaderný faktor 1-alfa $x genetika $x metabolismus $7 D051538
650    12
$a promotorové oblasti (genetika) $x genetika $7 D011401
650    12
$a diabetes mellitus 2. typu $x genetika $x metabolismus $7 D003924
650    _2
$a regulace genové exprese $7 D005786
650    _2
$a vazebná místa $7 D001665
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a vazba proteinů $7 D011485
655    _2
$a časopisecké články $7 D016428
700    1_
$a Molnes, Janne $u Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway $u Department of Medical Genetics and
700    1_
$a Tjora, Erling $u Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway $u Department of Pediatrics and Adolescent Medicine, Haukeland University Hospital, Bergen, Norway
700    1_
$a Raasakka, Arne $u Department of Biomedicine and
700    1_
$a Myllykoski, Matti $u Department of Biomedicine and
700    1_
$a Colclough, Kevin $u Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom
700    1_
$a Saint-Martin, Cécile $u Department of Medical Genetics, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, DMU BioGeM, Paris, France $u Monogenic Diabetes Study Group of the Société Francophone du Diabète, Paris, France
700    1_
$a Adelfalk, Caroline $u Clinical Genetics, Pathology and Molecular Diagnostics, University Hospital Skåne, Lund, Sweden
700    1_
$a Dusatkova, Petra $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Pruhova, Stepanka $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Valtonen-André, Camilla $u Clinical Chemistry and Pharmacology, University Hospital Skåne, Lund, Sweden
700    1_
$a Bellanné-Chantelot, Christine $u Department of Medical Genetics, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, DMU BioGeM, Paris, France $u Monogenic Diabetes Study Group of the Société Francophone du Diabète, Paris, France
700    1_
$a Arnesen, Thomas $u Department of Biomedicine and $u Department of Surgery, Haukeland University Hospital, Bergen, Norway
700    1_
$a Kursula, Petri $u Department of Biomedicine and $u Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Oulu, Finland
700    1_
$a Njølstad, Pål Rasmus $u Mohn Center for Diabetes Precision Medicine, Department of Clinical Science, University of Bergen, Bergen, Norway $u Section of Endocrinology and Metabolism, Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway
773    0_
$w MED00194017 $t JCI insight $x 2379-3708 $g Roč. 9, č. 11 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38855865 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134322 $b ABA008
999    __
$a ok $b bmc $g 2143384 $s 1225403
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 9 $c 11 $e 20240610 $i 2379-3708 $m JCI insight $n JCI Insight $x MED00194017
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options